Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference

  • VMB-100 shows therapeutic potential in Stress Urinary Incontinence
  • RNA engineering technology enhances the potency of mRNA

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces that its Chief Scientific Officer, Friedrich Metzger, will be presenting data on its mRNA engineering technology and lead therapeutic candidate, VMB-100, at the 9th International mRNA Health Conference taking place on 9th and 10th November 2021 in Berlin.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...